

Supplemental Digital Content 4 (table)

Adverse events after quadrivalent HPV vaccination among girls living with HIV.

| | | Ever Reported | After Dose 1 | After Dose 2 | After Dose 3 |
|-------------------|--------------------------|---------------|--------------|--------------|--------------|
| | | N=35 | N=35 | N=34 | N=33 |
| Any adverse event | | 17 (48.6%) | 15 (42.9%) | 13 (38.2%) | 12 (36.4%) |
| Injection site | Any | 16 (45.7%) | 13 (37.1%) | 13 (38.2%) | 11 (33.3%) |
| | Pain | 16 (45.7%) | 12 (34.3%) | 13 (38.2%) | 11 (33.3%) |
| | Swelling | 1 (2.9%) | 1 (2.9%) | 1 (2.9%) | 0 |
| | Redness | 1 (2.9%) | 1 (2.9%) | 1 (2.9%) | 1 (3.0%) |
| Systemic | Any | 5 (14.3%) | 3 (8.6%) | 3 (8.8%) | 2 (6.1%) |
| | Fatigue | 4 (11.4%) | 0 | 3 (8.8%) | 2 (6.1%) |
| | Headache | 4 (11.4%) | 1 (2.9%) | 3 (8.8%) | 1 (3.0%) |
| | Elevated CK ^a | 1 (2.9%) | 0 | 0 | 1 (3.0%) |
| | Fever | 1 (2.9%) | 1 (2.9%) | 0 | 0 |
| | Gastrointestinal | 1 (2.9%) | 1 (2.9%) | 1 (2.9%) | 0 |
| | Hives | 1 (2.9%) | 1 (2.9%) | 0 | 0 |

^a Creatine kinase